KAYTUS
21.5.2024 12:18:30 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, introduced at ISC High Performance 2024 its high-density computing server KR1280V2. It supports 32 E1.S SSDs, achieving an impressive flash memory density of 512TB in a 1U form factor. Compared to the last generation, KR1280V2 adopts low latency storage and network design, doubling the high concurrency I/O performance for LLM training scenarios, and improving model training efficiency.
This 1U2S flagship server is powered by the latest Intel, AMD, or ARM processors. The KR1280V2 features an optimized cooling strategy to support CPUs with the highest TDP across platforms, without configuration restrictions. It also introduces a novel front I/O configuration, enhancing scalability with 8 PCIe 5.0 expansion cards and improving maintenance efficiency in data centers. The server’s drive tray type has been optimized to offer an innovative storage configuration of 12 front SFF drives, increasing storage density by 20%.
Supports 32 E1.S SSDs without performance degradation, delivering tens of millions IOPS
Powered by 5th Gen Intel® Xeon® processors and boasting remarkable computing density, the KR1280V2 supports up to 32 all-flash E1.S SSDs directly connected to CPUs within a 1U form factor. This configuration harnesses the full I/O rate of PCIe 5.0, maximizing throughput between CPUs and storage, achieving up to 160GB/s storage throughput. With load balancing across two OCP 3.0 cards, it doubles network bandwidth, catering to diverse data storage and processing needs while enhancing overall computing performance by 60%.
With ultimate flash memory density, the KR1280V2 effectively doubles LLMs' high concurrency performance
The KR1280V2 achieves tens of millions of IOPS performance in distributed storage scenarios, marking a remarkable 77% improvement. Deploying KR1280V2 servers for large-scale LLMs training ensures a twofold increase in high-concurrency I/O performance compared to the previous generation. As the number of GPUs and workload increases, the KR1280V2's latency curve becomes smoother and more predictable, demonstrating a notable 13% improvement in data latency also compared to the prior generation. These significant advancements enhance data preparation efficiency, model training, and data management while reducing wasted storage space. Consequently, it delivers robust storage capacity and performance for innovative LLM applications and better supports Java-based business scenarios requiring massive data, low latency, and high concurrency, such as in finance, cloud services, enterprises, and other data center applications.
Optimized cooling technologies and exceptional business reliability and sustainability
In terms of heat dissipation, the KR1280V2 supports multiple cooling methods, including EVAC heatsink air cooling, cold-plated liquid cooling, and single-phase immersion liquid cooling. It achieves an 8% to 12% power reduction through fan partition regulation, one-click BIOS optimization, and other techniques across 17 energy-efficient scenarios. Additionally, the KR1280V2 employs numerous advanced technologies to enhance stability and security. It introduces the exceptional MUPR2.0 early detection memory fault function, which utilizes a more comprehensive memory scrubbing technique to self-check and fix memory faults, achieving a broader range of error correction and a higher level of system protection. Consequently, the system's downtime rate is 69% lower than the industry average.
To learn more about the KAYTUS KR1280V2 high-density server, please visit the website.
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521588996/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom